Interleukin-12/23 monoclonal antibody for psoriasis [9]

New England Journal of Medicine

Volumn 356, Issue 19, 2007, Pages 2003-

  Okamoto, Hiroshi ^a   Momohara, Shigeki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY INTERLEUKIN 12; MONOCLONAL ANTIBODY INTERLEUKIN 23; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LETTER; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS;

EID: 34248374094     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc070648     Document Type: Letter

References (4)

1. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92.
2. Spadaro A, Rinaldi T, Riccieri V, Valesini G, Taccari E. Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis. Ann Rheum Dis 2002;61:174-6.
3. McInnes IB, Liew FY. Cytokine networks - towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1:31-9.
4. Wada Y, Lu R, Zhou D, et al. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood 2007;109:1156-64.